Physician profile
Cesar E Mendoza
NPI 1275599953
$4,018.03
in general payments reported to CMS, 2019-2025
30 companies · $500 in 2025
The $500 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $448 · 2021: $383 · 2022: $898 · 2023: $404 · 2024: $337 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $742.96 | 2019-2025 | Amplatzer Amulet, Navitor, Cardiomems |
| Angiodynamics, INC. | $366.26 | 2019-2022 | |
| Pfizer INC. | $361.43 | 2019-2023 | |
| Medtronic, INC. | $239.21 | 2022-2023 | Closurefast |
| Amgen INC. | $227.61 | 2020-2025 | Repatha, Repatha |
| Celonova Biosciences, INC. | $207.41 | 2019 | |
| Medtronic Vascular, INC. | $196.81 | 2019 | |
| Inari Medical, INC. | $186.75 | 2022 | |
| Edwards Lifesciences Corporation | $174.08 | 2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $173.79 | 2020-2025 | Camzyos, Eliquis |
| Microport Crm USA INC | $135.59 | 2020 | |
| Terumo Medical Corporation | $133.92 | 2019-2023 | Heartrail, Angio-Seal, Optitorque |
| Biotronik INC. | $131.64 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $124.76 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $93.91 | 2019-2025 | Wainua |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $83.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $73.73 | 2022-2024 | |
| Ge Healthcare | $65.86 | 2019-2020 | |
| Shockwave Medical, INC | $53.61 | 2021 | |
| Boston Scientific Corporation | $41.33 | 2022-2025 | Farapulse |
| Penumbra, INC. | $40.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $30.29 | 2025 | Opsumit, Uptravi |
| Asahi Intecc USA, INC. | $27.16 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $22.39 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $21.84 | 2024 | Arcalyst |
| Atricure, INC. | $19.65 | 2023 | |
| Baxter Healthcare | $15.08 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Siemens Medical Solutions USA, INC. | $12.18 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9.00 | 2020 | |
| Cardiovascular Systems INC. | $6.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.